# Study to Assess Adverse Events When Subcutaneous Risankizumab Injection is Given to Adult Participants With Psoriasis in Real World Setting

> **NCT04799990** · — · WITHDRAWN · sponsor: **AbbVie**

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** Risankizumab
- **BIOLOGICAL:** Comparator 1
- **DRUG:** Comparator 2

## Key facts

- **NCT ID:** NCT04799990
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-06-23
- **Primary completion:** 2022-03-10
- **Final completion:** 2022-03-10
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study is not recruiting and using secondary data sources only
- **Last updated:** 2022-12-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04799990

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04799990, "Study to Assess Adverse Events When Subcutaneous Risankizumab Injection is Given to Adult Participants With Psoriasis in Real World Setting". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04799990. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*